Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients

Informazioni relative al progetto

XTremedy Medical

ID dell’accordo di sovvenzione: 101069625

DOI

10.3030/101069625

Progetto chiuso

Data della firma CE 20 Giugno 2022

Data di avvio 1 Luglio 2022

Data di completamento 31 Dicembre 2022

Finanziato da

• European innovation ecosystems

Costo totale

Nessun dato

Contributo UE

€ 75 000,00

Coordinato da

XTREMEDY MEDICAL LIMITED
Ireland

Periodic Reporting for period 1 - XTremedy Medical (Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients)

Periodo di rendicontazione: 2022-07-01 al 2022-12-31

Sintesi del contesto e degli obiettivi generali del progetto

XTremedy Medical are a surgical device company developing treatments for infected wounds, in particular Diabetic Foot Ulcers (DFUs). Infection has now been recognised as a leading cause of wound chronicity - wounds that do not respond to initial treatments.i Infections that spread to deep muscle and bone tissues, are the leading cause of amputations in diabetics. Biofilms, a type of infection often found in wounds, are complex to treat with up to 1000-fold tolerance to antibiotics.ii High concentrations of antibiotics required to treat these infections impairs kidney function and leads to high rates of kidney failure.
XTremedy Medical overcomes limitations with current solutions by treating both surface and subsurface tissues without disrupting tissue structures. XTremedy’s first device – BioBlate, is a non-thermal ablation device using pulsed electric field ablation (PFA) to treat biofilms. PFA is known for its anti-microbial and non-destructive properties.
Incorporating BioBlate technology enables the surgeon to remove all biofilm within the wound without removing excess healthy tissue which impairs healing. Delivering wound margins free of biofilm leads to fewer surgeries and shortened hospital stays

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Commercialisation (regulatory and market access) strategy mapped for BioBlate technology

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Xtremedy have demonstrated that thier PFA device is up to 1000x more effective at removing biofilm/bioburden than the standard of care (saline flush). Using the BioBlate device, the team achieved 6 log reductions in ex-vivo staph epidermis biofilms and 4 log reductions in staph aureus. This is compared to <1 log reduction with the standard of care, a saline flush. These results have been validated in a third party lab.